Background
Long-acting injectable ART (LA-ART) may reduce barriers to medication adherence for postpartum women with HIV (PPWH) and thus reduce vertical transmission (VT) and improve health outcomes. With CEPAC, a validated computer model of mother-child pairs, we estimated the clinical outcomes and cost-effectiveness of LA-ART for breastfeeding PPWH with adherence challenges to oral ART in Zimbabwe.
Methods
At time of delivery, we simulated 2 cohorts of women who had been engaged in antenatal care, had adherence challenges while prescribed oral tenofovir/lamivudine/dolutegravir (TLD) in pregnancy, and had no prior NNRTI exposure, along with their infants: 1) women not virally suppressed at the time of delivery (NVS) and 2) women with viral suppression at delivery (VS). We modeled 2 ART approaches immediately after delivery: standard of care (SOC: continuation of TLD) and LA-ART (switching from TLD to cabotegravir/rilpivirine [LA-CAB/RPV]). Key inputs included: 6-month postpartum suppression (RNA <50c/ml) for CAB/RPV (NVS: 85%, VS: 90%) and TLD (NVS: 63%, VS: 78%); monthly ART costs (LA-CAB/RPV: $12, TLD: $3.60); 24-month postpartum engagement in care (NVS: 70%, VS: 79%); 18-month breastfeeding duration; and vertical transmission (VT) risk (0.06%-0.89%/month of breastfeeding, range by maternal RNA). Primary outcomes included VT; pediatric life expectancy (pLE); total costs, defined as maternal drug costs in breastfeeding and pediatric HIV-related lifetime care costs; and incremental cost-effectiveness ratios (ICERs: $/life-years saved (LYS), defining cost-effective as ICER <$840/YLS (0.5xGDP).
Results
LA-ART reduced projected VT compared to SOC: from 8.07% to 6.59% (NVS) and from 4.18% to 3.81% (VS), averting ~200 infections/year in Zimbabwe (Table). For NVS, LA-ART improved pLE (SOC: 65.93y, LA-ART: 66.37y) while saving money (SOC: $770/child, LA-ART: $760/child); LA-ART would not be cost-effective if CAB/RPV cost >$23/month or 6-month suppression was <68%. For VS, LA-ART led to higher projected pLE and costs (67.51y, $550/child) than SOC (67.39y, $450/child), with ICER $2,500/LYS; LA-ART would become cost-effective if CAB/RPV cost <$7/month.
Conclusions
LA-ART for breastfeeding women with adherence challenges to oral TLD could reduce infant infections. If efficacy is confirmed in postpartum women, LA-ART for women without viral suppression at delivery would improve outcomes and save money; for women with viral suppression, it would be cost-effective in Zimbabwe if costs were ≤$7/month.
Table or Figure
![]()